As FDA weighs another myeloma endpoint for accelerated approvals, experts say timely access is at stake

Now, after nearly a decade of work, Landgren and other researchers will share research that aims to substantiate a link between MRD negativity and improved clinical outcomes such as delayed tumor progression or death in multiple myeloma. A team led by Landgren, now with the Sylvester Comprehensive Cancer Center, and another International Myeloma Foundation-backed group known as i2TEAMM, will present their separate meta-analysis studies of MRD in myeloma at an FDA advisory committee meeting this Friday.